NYSE:ABT

Abbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee

Retrieved on: 
Monday, April 29, 2024
Stent, FDA, Leg, Education, Physician, Knee, Esprit, TCT, Everolimus, Food, PAD, Survival rate, Breast, Columbia University, Conference, Foot, Disease, Amputation, Oxygen, Standard of care, Artery, Plaque, Peripheral artery disease, BTK, CLTI, Pharmaceutical industry

The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.

Key Points: 
  • The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.
  • Until today, there were no stents or drug-coated balloons approved for use below the knee in the U.S.
  • The Esprit BTK System is a first-of-its-kind dissolvable stent and is comprised of material similar to dissolving sutures.
  • That's why we're revolutionizing treatments with resorbable scaffold technology below the knee," said Julie Tyler, senior vice president of Abbott's vascular business.

Abbott Receives FDA Approval for TriClip™, First-of-Its-Kind Device to Repair Leaky Tricuspid Heart Valve

Retrieved on: 
Tuesday, April 2, 2024
Disease, Atrial fibrillation, Risk, Anatomy, Patient, Aortic stenosis, Endoclip, Tricuspid regurgitation, Structural heart disease, Death, Tricuspid valve, Abbott Northwestern Hospital, Quality of life, Heart failure, Leg, Heart, MitraClip, Safety, Fatigue, Blood, FDA, Physician, Food, Pharmaceutical industry

The tricuspid valve controls blood as it flows from the heart's right atrium to the right ventricle.

Key Points: 
  • The tricuspid valve controls blood as it flows from the heart's right atrium to the right ventricle.
  • TR occurs when the valve doesn't close properly, causing a leak and allowing blood to flow backward in the heart.
  • TR can force the heart to work harder, causing debilitating symptoms such as fatigue and shortness of breath.
  • TriClip has been approved for use in more than 50 countries, including in Europe and Canada, since its initial CE Mark approval in 2020.

Abbott Receives FDA Clearance for Whole Blood Rapid Test to Help with Assessment of Concussion at the Patient's Bedside

Retrieved on: 
Monday, April 1, 2024
Brain, Plasma, Head, L1, Concussion, Serum, GFAP, Patient, Biomarker, Research, TBI, Triage, University, Neurosurgery, Doctor of Philosophy, Glial fibrillary acidic protein, Head Injuries, Pediatrics, Traumatic brain injury, Hospital, San Francisco General Hospital, Glasgow Coma Scale, FDA, Health, Food, Medical imaging

The whole blood test on a portable instrument helps clinicians evaluate patients 18 years of age and older who present with suspected mild traumatic brain injury or mTBI, commonly known as concussion.

Key Points: 
  • The whole blood test on a portable instrument helps clinicians evaluate patients 18 years of age and older who present with suspected mild traumatic brain injury or mTBI, commonly known as concussion.
  • Test results can help rule out the need for a CT scan of the head and assist in determining the best next steps for patient care.
  • The i-STAT TBI cartridge with the i-STAT Alinity System requires a small venous blood sample, which is applied to the test cartridge.
  • Now, we have a whole blood test that can help assess the brain right at the patient's bedside – expanding access to more health providers and therefore patients."

Abbott Hosts Conference Call for First-Quarter Earnings

Retrieved on: 
Wednesday, March 27, 2024

ABBOTT PARK, Ill., March 27, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2024 financial results on Wednesday, April 17, before the market opens.

Key Points: 
  • ABBOTT PARK, Ill., March 27, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2024 financial results on Wednesday, April 17, before the market opens.
  • The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com .
  • An archived edition of the call will be available later that day.

Real-World Data Show Abbott's FreeStyle Libre® Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes

Retrieved on: 
Wednesday, March 6, 2024
CGM, Blood, Glucose meter, Treatment, Weight loss, Glycated hemoglobin, Food, Conference, Behavior, Type 2 diabetes, ATTD, Type 2, Smartphone, Patient, Insulin, Heart, Continuous glucose monitor, Appetite, Pharmaceutical industry

These findings were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) held in Florence, Italy, on March 6, 2024.

Key Points: 
  • These findings were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) held in Florence, Italy, on March 6, 2024.
  • GLP-1 medicines – also known as glucagon-like peptide-1 receptor agonist (GLP-1 RA) - are increasingly being prescribed for people with Type 2 diabetes as they provide glycemic benefit and support weight loss.
  • "While treating my patients, I've observed that when we've added a CGM, like the FreeStyle Libre technology, to their GLP-1 therapy, we see even better glycemic control.
  • To maximize the benefits of GLP-1 medicines, it's worth considering the combination of a CGM to support people who live with Type 2 diabetes."

New Study Shows Mixed Reality Technology for Blood Donation from Abbott and Blood Centers of America Helps Ease Stress, Encourages People to Donate Again

Retrieved on: 
Thursday, February 1, 2024
Johns Hopkins University, Anxiety, Quad Cities, Needle, Research, Fear, Transfusion, Flower, Environment, Music, Stanford University, University School, Blood, BCA, Plasma, Seed, Medical device

Abbott, the global leader in screening blood and plasma, partnered with Blood Centers of America, the largest blood supplier network in the U.S., to launch a mixed reality experience for blood donors in June 2023.

Key Points: 
  • Abbott, the global leader in screening blood and plasma, partnered with Blood Centers of America, the largest blood supplier network in the U.S., to launch a mixed reality experience for blood donors in June 2023.
  • The Abbott and BCA mixed reality innovation is an immersive digital experience designed to improve the blood donation process, attract new donors and motivate a younger generation to give blood.
  • Donors wear lightweight mixed reality headsets to visit a digital world while remaining fully aware of their real-world surroundings.
  • The mixed reality experience allows blood donation professionals to safely conduct the donation and interact with donors at every step of the process.

Abbott Launches New PROTALITY™ Brand to Support Adults on Their Weight Loss Journey

Retrieved on: 
Wednesday, January 31, 2024
Mineral, Weight loss, Vitamin, Agonal respiration, ShopRite, Overweight, Research, Obesity, CVS, Snack, Kroger, Micronutrient, Food, Nutrient, Appetite, MSC, MBA, High, Facial muscles, Skin, MPH, RDA, Amazon (company), Metabolism, Types of chocolate, Skeletal muscle, Health, Movement, Dietary supplement

The high-protein nutrition shake is the first product in this line to support the growing number of adults interested in pursuing weight loss while maintaining muscle mass and good nutrition.

Key Points: 
  • The high-protein nutrition shake is the first product in this line to support the growing number of adults interested in pursuing weight loss while maintaining muscle mass and good nutrition.
  • We understand that a weight loss journey can be challenging, which is why we're launching the PROTALITY brand to give adults nutritional products with an excellent source of high-quality protein and nutrients to support muscle health.''
  • Each PROTALITY shake has key nutrients to support weight loss journeys:
    ''As people start to see results from their weight loss programs, many look for ways to maintain progress, including their nutrition goals,'' added Williams.
  • Individuals on a weight loss journey should always discuss their nutritional plan with their healthcare provider.

Abbott Launches World's Smallest Rechargeable System With Remote Programming Capabilities to Treat Movement Disorders¹+

Retrieved on: 
Thursday, January 25, 2024
Patient, Research, DBS, DSM-IV codes, Communication, University, Parkinson's disease, PINS, Food, Deep brain stimulation, Travel, Movement, Neurosurgery, FDA, Wi-Fi, Boston Scientific, Essential tremor, Movement disorder, IOS, Use

"The Liberta RC DBS system excels in both areas, as a compact rechargeable device with the lowest recharge requirement of any FDA-approved DBS system.

Key Points: 
  • "The Liberta RC DBS system excels in both areas, as a compact rechargeable device with the lowest recharge requirement of any FDA-approved DBS system.
  • This achievement, coupled with the integration of remote programming capabilities, is a significant advancement for patients."
  • "In developing the Liberta RC DBS system, our focus has been on the unique experiences of individuals with chronic conditions like movement disorders," said Pedro Malha, vice president, neuromodulation, Abbott.
  • This system exemplifies our drive to providing patient-first solutions, combining effective therapy, effortless recharging, and remote programming capabilities."

Tandem Diabetes Care’s t:slim X2™ Insulin Pump is the First Automated Insulin Delivery System to Integrate with Abbott’s New FreeStyle Libre® 2 Plus Sensor

Retrieved on: 
Monday, January 8, 2024
Wearables, Mobile Technology, Technology, Mobile, Wireless, Medical Devices, Diabetes, Health Technology, Software, Biotechnology, Health, Continuous glucose monitor, Personal, Multimedia, CGM, Caregiver, DME, AID, Disease, Hyperglycemia, Internet, Tandem Diabetes Care, Control, FreeStyle, Medical device

(NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that the t:slim X2 insulin pump with Control-IQ technology is the first automated insulin delivery (AID) system to integrate with the newly available FreeStyle Libre 2 Plus sensor, Abbott’s latest continuous glucose monitoring (CGM) technology.

Key Points: 
  • (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that the t:slim X2 insulin pump with Control-IQ technology is the first automated insulin delivery (AID) system to integrate with the newly available FreeStyle Libre 2 Plus sensor, Abbott’s latest continuous glucose monitoring (CGM) technology.
  • View the full release here: https://www.businesswire.com/news/home/20240108667517/en/
    t:slim X2 Insulin Pump from Tandem Diabetes Care with Abbott’s Freestyle Libre 2 Plus sensor integration now available in the United States.
  • (Photo: Business Wire)
    Tandem’s t:slim X2 insulin pump connects wirelessly to the FreeStyle Libre 2 Plus sensor, which sends automatic glucose readings every minute2,3 to the pump.
  • FreeStyle Libre 2 Plus sensor connects via Bluetooth to the Tandem t:slim X2 insulin pump.

Abbott Hosts Conference Call for Fourth-Quarter Earnings

Retrieved on: 
Wednesday, January 3, 2024

ABBOTT PARK, Ill., Jan. 3, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter 2023 financial results on Wednesday, Jan. 24, before the market opens.

Key Points: 
  • ABBOTT PARK, Ill., Jan. 3, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter 2023 financial results on Wednesday, Jan. 24, before the market opens.
  • The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com .
  • An archived edition of the call will be available later that day.